Antibody Concentrations Decrease 14-Fold in Children With Celiac Disease on a Gluten-Free Diet but Remain High at 3...

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Celiac Disease Research

Background:

• Celiac disease diagnosis in children often relies on IgA against tissue transglutaminase (IgA-TTG) serologic tests.
• Antibody levels typically do not normalize within months of initiating a gluten-free diet (GFD).
• Effective short-term adherence predictors for GFD are needed for optimal pediatric celiac disease management.

Purpose of the Study:

• To evaluate the early serologic response to a GFD in children diagnosed with celiac disease.
• To determine if antibody levels (IgA-TTG and IgG against deamidated gliadin) change significantly within three months of GFD initiation.
• To assess the utility of antibody level changes as predictors of GFD adherence.

Main Methods:

• A prospective study observed 345 pediatric patients (mean age 8.4 years) confirmed for celiac disease via duodenal biopsy.
• Baseline serum samples were tested for IgA-TTG and IgG against deamidated gliadin.
• Follow-up serologic analyses were conducted approximately three months after initiating a GFD.

Main Results:

• Geometric mean IgA-TTG concentration decreased by a factor of 14.0 (from 72.4-fold to 5.2-fold ULN) within three months.
• A substantial IgA-TTG response was observed in 80.6% of children, but levels remained above 1-fold ULN in 83.8%.
• Only 28.1% of patients showed a substantial IgG response, indicating IgA-TTG is a more sensitive marker for early GFD adherence.

Conclusions:

• Serum IgA-TTG concentrations decrease substantially in most children with celiac disease on a GFD within three months.
• While antibody levels decrease, they often do not normalize, highlighting the need for careful monitoring.
• Changes in IgA-TTG levels provide valuable short-term data for assessing patient response to a GFD.